Evidence map›Paper›PMID 29207659›Full record

ArticleOncotarget2017

2-(3, 4-dihydroxybenzylidene)malononitrile as a novel anti-melanogenic compound.

Bonggi Lee, Kyoung Mi Moon, Jong Seung Lim, Yeojin Park, Do Hyun Kim, Sujin Son, Hyoung Oh Jeong, Dae Hyun Kim, Eun Kyeong Lee, Ki Wung Chung and 9 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 25 citations in OpenAlex.

  1. Response ofAntioxidants (Basel, Switzerland) · 2022
    Article
  2. Article
  3. Article
  4. Catechin-7-International journal of medical sciences · 2022
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 4 institutions in 2 countries.

Bonggi LeeMolecular Inflammation Research Center for Aging Intervention (MRCA), Pusan National University, Busan, Republic of Korea.
Kyoung Mi MoonCollege of Pharmacy, Pusan National University, Busan, Republic of Korea.
Jong Seung LimCollege of Pharmacy, Pusan National University, Busan, Republic of Korea.
Yeojin ParkCollege of Pharmacy, Pusan National University, Busan, Republic of Korea.
Do Hyun KimMolecular Inflammation Research Center for Aging Intervention (MRCA), Pusan National University, Busan, Republic of Korea.
Sujin SonMolecular Inflammation Research Center for Aging Intervention (MRCA), Pusan National University, Busan, Republic of Korea.
Hyoung Oh JeongCollege of Pharmacy, Pusan National University, Busan, Republic of Korea.
Dae Hyun KimMolecular Inflammation Research Center for Aging Intervention (MRCA), Pusan National University, Busan, Republic of Korea.
Eun Kyeong LeeCollege of Pharmacy, Pusan National University, Busan, Republic of Korea.
Ki Wung ChungCollege of Pharmacy, Pusan National University, Busan, Republic of Korea.
Hye Jin AnCollege of Pharmacy, Pusan National University, Busan, Republic of Korea.
Pusoon ChunCollege of Pharmacy, Inje University, Gimhae, Gyeongnam, Republic of Korea.
Arnold Y SeoJanelia Research Campus, Howard Huge Medical Institute, Ashburn, VA, USA.
Ju-Hye YangKorean Medicine (KM)-Application Center, Korea Institute of Oriental Medicine (KIOM), Dong-gu, Daegu, Korea.
Bong-Seon LeeKorean Medicine (KM)-Application Center, Korea Institute of Oriental Medicine (KIOM), Dong-gu, Daegu, Korea.
Jin Yeul MaKorean Medicine (KM)-Application Center, Korea Institute of Oriental Medicine (KIOM), Dong-gu, Daegu, Korea.
Won-Kyung ChoKorean Medicine (KM)-Application Center, Korea Institute of Oriental Medicine (KIOM), Dong-gu, Daegu, Korea.
Hyung Ryong MoonMolecular Inflammation Research Center for Aging Intervention (MRCA), Pusan National University, Busan, Republic of Korea.
Hae Young ChungMolecular Inflammation Research Center for Aging Intervention (MRCA), Pusan National University, Busan, Republic of Korea.
Pusan National University · KRKorea Institute of Oriental Medicine · KRInje University · KRJanelia Research Campus · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tyrosinase is a key player in ultraviolet-induced melanogenesis. Because excessive melanin accumulation in the skin can induce hyperpigmentation, the development of tyrosinase inhibitors has attracted attention in cosmetic-related fields. However, side effects including toxicity and low selectivity have limited the use of many tyrosinase inhibitors in cosmetics. We synthesized 12 novel 2-(substituted benzylidene)malononitrile derivatives and investigated their anti-melanogenic activities. Of these 12 compounds, 2-(3, 4-dihydroxy benzylidene)malononitrile (BMN11) exhibited the strongest inhibitory activity against tyrosinase (IC

Indexed as

melanogenesisphotoagingpigmentationskintyrosinase inhibitor

Identifiers

PMID29207659
PMCPMC5710939
OpenAlexW2753019364

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.